This has implications for the targeting of the IL-33/IL1RL1 axis inhibitors to a subset of patients of a specific genotype likely to gain the greatest clinical benefit and is highly relevant, with multiple pharmaceutical companies developing anti–IL-33/IL1RL1 approaches for the treatment of asthma. This evidence concerns the gene IL1RL1 and asthma.